Is Veozah Legit? What the FDA's Boxed Warning, Lawsuits, and Patient Complaints Actually Show

"Is it legit" means something different for a drug than for a telehealth brand. Veozah is not a subscription or a compounding pharmacy. It is a brand-name pill made by Astellas Pharma, and the FDA approved it in May 2023. Any US pharmacy can fill it with a prescription. So there is no Trustpilot score or Better Business Bureau file to check. The real questions are different. How serious is the liver warning? What do patients say? And where do the lawsuits stand?

Does Veozah cause liver damage? What the FDA boxed warning says

Veozah was approved without a liver warning. The FDA added one later, based on reports from real-world use. On September 12, 2024, it issued a safety alert about one patient. That patient developed serious liver injury about 40 days after starting Veozah. The symptoms included tiredness, nausea, itching, yellow skin and eyes, pale stools and dark urine. They slowly went away after the drug was stopped.

On December 16, 2024, the FDA raised this to a boxed warning. A boxed warning is the strongest warning a drug label can carry. It sits in a black frame at the top of the prescribing information.

The current label, revised in February 2026, describes several cases of this kind. All began within about 40 days of the first dose. All improved after the drug was stopped.

Liver enzymes are proteins that leak into the blood when liver cells are under stress. In the trials, they rose above three times normal in 2.3% of women on Veozah. On a dummy pill, or placebo, 0.9% of women had the same rise. Most of these women had no symptoms.

A boxed warning does not mean liver injury is common. It means the risk is serious enough that every prescriber and patient should see it first. UK regulators reached the same view. In April 2025, they asked for liver checks before and during treatment.

What liver tests will you need on Veozah?

Before your first fill, your clinician orders a liver blood panel. It measures ALT and AST, the two main liver enzymes. It also measures alkaline phosphatase and bilirubin, a yellow pigment the liver clears.

You should not start Veozah if ALT, AST or total bilirubin is already at twice the upper limit of normal. The upper limit of normal is the top of the lab's healthy range. After that first panel, the label asks for the same tests on a set schedule:

• Months 1, 2 and 3: once a month.
• Month 6: once.
• Month 9: once.

Your clinician stops Veozah if ALT or AST climbs above five times the upper limit. The drug also stops if they pass three times the upper limit while bilirubin is above twice normal.

The label also tells you to stop Veozah and get care right away if you notice signs of liver trouble:

• New tiredness
• Loss of appetite
• Nausea or vomiting
• Itching
• Yellow skin or eyes, called jaundice
• Pale stools or dark urine
• Belly pain

In the reported cases, symptoms eased once the drug was stopped. The test schedule is built to catch a problem early, before it gets worse.

Who should not take Veozah?

The February 2026 label lists three contraindications. A contraindication means the drug must not be used at all. The boxed warning adds a fourth rule about liver tests.

• Cirrhosis of any degree. Cirrhosis is lasting scarring of the liver. The ban includes its mildest stage, called Child-Pugh A.
• Severe kidney disease or kidney failure. Mild or moderate kidney disease needs no dose change.
• Any drug that blocks CYP1A2. CYP1A2 is a liver enzyme that clears Veozah from the body. Blocking it, even weakly, raises Veozah levels. The label names fluvoxamine, an antidepressant, mexiletine, a heart-rhythm drug, and cimetidine, an acid reducer.
• Liver tests already at twice normal or higher. The boxed warning says not to start Veozah in that case.

The SKYLIGHT trials behind the approval left out women with liver disease or high liver enzymes, as the trial registry shows. That is a normal trial choice. It also means real-world use reached a wider group than the trials did. That is partly why the liver signal appeared only after approval.

What do real patients complain about with Veozah?

On Drugs.com, Veozah averages 7.4 out of 10 in patient reviews. A little over half are positive. Fewer than one in ten are negative. It is a small sample, under 70 reviews.

The most common complaints are ordinary for a prescription drug:

• Nausea
• Headache
• Trouble sleeping
• Dizziness
• Back or tailbone pain

One pattern is worth knowing before you start. Some women describe strong relief at first that fades after three to six months. Their hot flashes creep back despite daily use. Not everyone has this, but it comes up often enough to mention.

What is missing is just as telling. Reviewers rarely describe liver injury of their own. Most liver mentions are advice to others to get tested.

We found no large, citable pattern of Reddit threads about Veozah. If you search r/menopause yourself, trust a detailed, dated post over a one-line "stay away."

Cost is the other big complaint

Reviewers often mention high cash prices and insurance denials. Here is what Veozah costs each month, rounded:

• With insurance through work or a private plan: $0 the first month with the Astellas savings card, then as little as $30. The card does not work with Medicare or Medicaid.
• Paying cash with a free discount card: about $465 at the cheapest pharmacy, using a card such as SingleCare.
• Paying cash with no discount: about $780.
• No insurance and limited income: Astellas' patient assistance program may cover it at no cost if you qualify.

The full breakdown of Veozah's cost covers coupons, Medicare and the approval steps insurers often require.

Is there a Veozah lawsuit or an FDA warning letter?

These are two different things. An FDA warning letter is an enforcement notice to a company, often about its marketing or its factories. A boxed warning is a safety label. As of October 2026, FDA's warning-letter database shows no letter about Veozah. The liver issue went through the normal label-update process instead.

Lawsuits are a separate story. Since the 2024 safety alert, several law firms have advertised for women who had liver problems on Veozah. Their claim is that Astellas should have warned sooner. Lawyers call this a failure-to-warn case.

No formal grouping of these cases exists yet. Veozah is not on the federal list of pending multidistrict litigation, or MDL, as of October 2026. An MDL is how federal courts gather many similar lawsuits under one judge. One firm has described the litigation as being in its early stages.

So read a law-firm ad for what it is. It shows lawyers looking for clients. It is not a settlement, a verdict or proof that the drug caused anyone's symptoms.

Is Veozah FDA-approved, or is it compounded?

Veozah is FDA-approved. It went through the standard new-drug review, backed by the SKYLIGHT phase 3 trials. Phase 3 trials are the large studies that decide approval. Astellas makes it as one finished product, under the same quality rules as any brand-name drug.

A compounded drug is a different category. A pharmacy mixes it to order, like a custom hormone cream. That is legal, but the FDA does not test and approve the finished product.

The boxed warning is a sign the safety system works. Monitoring after approval caught a rare signal. The label then changed in public, with records anyone can read.

Is Veozah safer than HRT or other hot flash treatments?

"No boxed warning" is not the bar most menopause drugs clear. Hormone therapy, or HRT, has long carried its own boxed warning. It grew out of the Women's Health Initiative study.

That warning is changing. In February 2026, the FDA approved the first updated hormone labels, starting with six products. They drop heart disease, stroke, breast cancer and probable dementia from the boxed warning. Estrogen-only pills and patches keep a boxed warning on uterine cancer. More labels are being updated.

So the real question is which risk fits your health history. Veozah's liver cases were caught by labs or symptoms and eased after stopping. HRT's risks are different in kind, and some are less quickly reversed. Neither is simply worse. They suit different women, and Veozah vs HRT compares them side by side.

Low-dose paroxetine, sold as Brisdelle, is the one older non-hormonal drug FDA-approved for hot flashes. Gabapentin, oxybutynin and clonidine are used off-label, meaning without FDA approval for this use. None of these carries a liver boxed warning. They have a longer track record, but less hot-flash-specific evidence than Veozah.

Veozah is also no longer the only drug of its kind. Lynkuet, or elinzanetant, is a Bayer capsule approved in October 2025 for moderate to severe hot flashes. It blocks the same brain signal as Veozah, plus a second one. Its label has no boxed warning. It does warn about sleepiness, liver enzyme rises and seizures. It must not be taken during pregnancy. Prices for both are on Veozah's real price, unpacked.

What to check before you start Veozah

• Baseline liver tests. Make sure they are done before your first fill. The label requires them.
• The test schedule. Write it down or set reminders: monthly for three months, then at months 6 and 9.
• Your full medication list. Include supplements. Flag fluvoxamine or any other CYP1A2 blocker, since the combination is not allowed.
• The warning signs listed above. Any of them means stopping Veozah and calling your prescriber that day.
• Law-firm ads, for what they are. They show lawyers building cases. They are not a finding of fault.

Put together, the record is reassuring. Veozah passed the FDA's standard review. Its boxed warning reflects a rare, serious liver risk caught after approval, which has eased once the drug was stopped. The required tests are specific and doable. No FDA warning letter has gone to Astellas over Veozah. No lawsuit has led to an MDL, a settlement or a verdict. The real complaints are side effects, fading relief for some women, and the price.